Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

65.70
+1.041.60%
Volume:776.86K
Turnover:50.80M
Market Cap:12.70B
PE:173.36
High:66.30
Open:65.92
Low:64.33
Close:64.67
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.88
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.01
PE(LYR):36.50

Loading ...

BioMarin price target raised to $120 from $110 at Evercore ISI

TIPRANKS
·
May 05

Morgan Stanley Trims Price Target on BioMarin Pharmaceutical to $119 From $120, Keeps Overweight Rating

MT Newswires Live
·
May 05

BioMarin Pharmaceutical Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Biomarin Pharmaceutical Inc : Morgan Stanley Cuts Target Price to $119.00 From $120.00

THOMSON REUTERS
·
May 05

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN) and Sanofi (OtherSNYNF)

TIPRANKS
·
May 05

GUIDANCE: (BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.85 - $5.05

MT Newswires Live
·
May 05

BioMarin Q1 revenue rises, beats estimates

Reuters
·
May 05

BioMarin Q1 GAAP net income drops 43% to $106 million; revenue rises 3% to $766 million

Reuters
·
May 05

Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate

Benzinga Earnings
·
May 05

Biomarin Pharmaceutical Outlook FY Adjusted EPS USD 4.85-5.05

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 EPS USD 0.54

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 Adjusted EPS USD 0.76 VS. Ibes Estimate USD 0.75

THOMSON REUTERS
·
May 05

Biomarin Pharmaceutical Q1 Net Income USD 106 Million

THOMSON REUTERS
·
May 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 04

How Investors Are Reacting To BioMarin (BMRN) VOXZOGO Data Showing Benefits Beyond Height in Achondroplasia

Simply Wall St.
·
May 04

BioMarin announces new research from studies of Voxzogo

TIPRANKS
·
May 04

BioMarin says VOXZOGO long-term trials improve arm span, maintain bone density in achondroplasia

Reuters
·
May 03

Biomarin Presents New Data on the Effect of Long-Term Treatment With Voxzogo® (Vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

THOMSON REUTERS
·
May 03

BioMarin Pharmaceutical Inc expected to post earnings of 79 cents a share - Earnings Preview

Reuters
·
May 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01